Almitas Capital LLC holds a focused book of 115 stocks worth $442.5M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened BIO RAD LABS INC and trimmed DESIGN THERAPEUTICS INC. Their largest long position is FIDELITY WISE ORIGIN BITCOIN at 20% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1596468/holdings"
Use Arkolith to show Almitas Capital LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
27% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Fidelity Wise Origin Bitcoin SHS | $90.7M | 1.54M | 20.5% | —Held | |
| 2 | BlackRock Mun Target Term TR COM SHS BEN IN | $33.7M | 1.49M | 7.6% | —Held | |
| 3 | ASA Gold And Precious MTLS L SHS | $32.6M | 525.7K | 7.4% | ▲+38% Added · +144K sh | |
| 4 | Amylyx Pharmaceuticals Inc COM | $29.5M | 2.12M | 6.7% | —Held | |
| 5 | Design Therapeutics Inc COM | $16.3M | 1.53M | 3.7% | ▼~0% Reduced · −100 sh | |
| 6 | Nuveen Pa Invt Quality Mun F COM | $12.6M | 1.06M | 2.9% | ▲+187% Added · +689K sh | |
| 7 | Pimco Dynamic Income Strateg COM SHS BEN INT | $11.9M | 541.5K | 2.7% | ▲+258% Added · +390K sh | |
| 8 | Lyell Immunopharma Inc COM NEW | $11.6M | 577.8K | 2.6% | —Held | |
| 9 | Bio Rad Labs Inc CL A | $8.4M | 30.3K | 1.9% | ▲New New position | |
| 10 | Cannae Hldgs Inc COM | $8.4M | 741.3K | 1.9% | ▲+80% Added · +329K sh | |
| 11 | Cornerstone Total Return FD COM | $7.8M | 1.12M | 1.8% | ▲13× Added · +1.0M sh | |
| 12 | BlackRock Health Sciences Te COM SHS | $7.3M | 506.4K | 1.6% | ▲+231% Added · +353K sh | |
| 13 | Alx Oncology Hldgs Inc COM | $6.4M | 3.17M | 1.4% | ▲+25% Added · +637K sh | |
| 14 | Brightspire Capital Inc COM CL A | $5.7M | 1.02M | 1.3% | ▼−1.3% Reduced · −14K sh | |
| 15 | Bny Mellon Strategic Mun BD COM | $5.6M | 926.3K | 1.3% | —Held | |
| 16 | MFS High Yield Mun TR SH BEN INT | $5.4M | 1.50M | 1.2% | —Held | |
| 17 | Pimco Calif Mun Income FD COM | $5.3M | 617.0K | 1.2% | ▼−3.7% Reduced · −24K sh | |
| 18 | Elme Communities SH BEN INT | $5.2M | 2.61M | 1.2% | ▲+158% Added · +1.6M sh | |
| 19 | Monroe Cap Corp COM | $5.2M | 1.28M | 1.2% | ▲+28% Added · +279K sh | |
| 20 | An2 Therapeutics Inc COM | $5.1M | 1.48M | 1.1% | —Held | |
| 21 | MFS High Income Mun TR SH BEN INT | $4.7M | 1.27M | 1.1% | ▲+6.1% Added · +73K sh | |
| 22 | Nyli Cbre GBL Infr Megtrnds COM | $4.6M | 316.1K | 1.0% | ▲+413% Added · +254K sh | |
| 23 | Japan Smaller Capitalization COM | $4.4M | 403.0K | 1.0% | ▼−7.6% Reduced · −33K sh | |
| 24 | Crescent Cap BDC Inc COM | $4.3M | 356.9K | 1.0% | ▼−20% Reduced · −87K sh | |
| 25 | DTF Tax-Free Income 2028 Ter COM | $4.1M | 355.1K | 0.9% | ▲+1.2% Added · +4K sh | |
| 26 | Mexico FD Inc COM | $3.8M | 183.5K | 0.9% | ▼−1.3% Reduced · −2K sh | |
| 27 | First TR SR FLTG Rate Income COM | $3.7M | 382.9K | 0.8% | ▲+335% Added · +295K sh | |
| 28 | Clough Global Opportunities SH BEN INT | $3.7M | 660.8K | 0.8% | ▼−16% Reduced · −129K sh | |
| 29 | MFS Invt Grade Mun TR SH BEN INT | $3.6M | 454.8K | 0.8% | ▼~0% Reduced · −80 sh | |
| 30 | FS Specialty Lending FD COM SH BEN INT | $3.4M | 268.8K | 0.8% | ▼−66% Reduced · −533K sh | |
| 31 | Pimco New York Mun FD II COM | $3.3M | 488.7K | 0.8% | ▲New New position | |
| 32 | Cornerstone Strategic Invest COM | $3.2M | 442.0K | 0.7% | ▲New New position | |
| 33 | Madison Square GRDN SPRT Cor CL A | $3.2M | 9.9K | 0.7% | —Held | |
| 34 | Central & Eastern Europe FD COM | $3.2M | 173.3K | 0.7% | —Held | |
| 35 | Nuveen Floating Rate Income COM | $3.1M | 411.6K | 0.7% | ▲+249% Added · +294K sh | |
| 36 | Ennis Inc COM | $3.0M | 139.0K | 0.7% | —Held | |
| 37 | Saba Capital Income & Opport COM NEW | $2.9M | 347.8K | 0.7% | ▲+442% Added · +284K sh | |
| 38 | Pgim Short Dur Hig Yld Opp F COM | $2.9M | 178.9K | 0.6% | ▲+608% Added · +154K sh | |
| 39 | Ladder Cap Corp CL A | $2.8M | 290.5K | 0.6% | ▲+53% Added · +101K sh | |
| 40 | TPG Re Fin TR Inc COM | $2.6M | 327.8K | 0.6% | ▲New New position | |
| 41 | Clough Global Equity FD COM | $2.5M | 331.0K | 0.6% | ▲+2.5% Added · +8K sh | |
| 42 | AllianceBernstein Natl Mun I COM | $2.3M | 214.3K | 0.5% | —Held | |
| 43 | First TR High Yield Opprt 20 COM | $2.2M | 166.3K | 0.5% | ▲+201% Added · +111K sh | |
| 44 | Playstudios Inc CLASS A COM | $2.2M | 4.70M | 0.5% | ▲+16% Added · +657K sh | |
| 45 | Liberty All Star Equity FD SH BEN INT | $2.2M | 395.5K | 0.5% | ▼−51% Reduced · −409K sh | |
| 46 | SRH Total Return Fund Inc COM | $2.0M | 116.8K | 0.5% | ▲+307% Added · +88K sh | |
| 47 | Bny Mellon Mun BD Infrastruc COM SHS | $1.9M | 182.9K | 0.4% | —Held | |
| 48 | Tejon Ranch Co COM | $1.8M | 95.0K | 0.4% | ▲+2.0% Added · +2K sh | |
| 49 | Alto Neuroscience Inc COM SHS | $1.8M | 78.5K | 0.4% | —Held | |
| 50 | Rallybio Corp COM | $1.7M | 191.2K | 0.4% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 115 | $442.5M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 107 | $454.2M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 17, 2025 | 66 | $436.9M | 13F-HR/A |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 82 | $396.4M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 81 | $301.4M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 92 | $456.3M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 69 | $283.0M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 15, 2024 | 76 | $240.5M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 14, 2024 | 69 | $242.1M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 116 | $290.2M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 21, 2023 | 88 | $208.8M | 13F-HR/A |
| Q2 2023 | Jun 30, 2023 | Aug 11, 2023 | 92 | $233.9M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 97 | $209.3M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 128 | $217.0M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 87 | $133.9M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 119 | $193.4M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 85 | $167.6M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 54 | $98.5M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 46 | $73.7M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 46 | $80.2M | 13F-HR |
| Q1 2020 | Mar 31, 2020 | May 14, 2020 | 46 | $45.2M | 13F-HR |
| Q4 2019 | Dec 31, 2019 | Feb 14, 2020 | 65 | $114.8M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.